ABIVAX confirms trading resumption
ABIVAX confirms trading resumption
May 2, 2017
DOWNLOAD AS A PDF 374.5 KB
Paris, May 2nd, 2017 at 7:00am CEST – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral diseases, confirms the resumption of trading effective as of Euronext Paris market opening at 9:00am CEST.
As a reminder, trading was suspended, as requested by the company and in agreement with the AMF (French Market Authority), on Friday April, 28th 2017 at 11:29am (CEST).
The company will also disclose top line results of ABX464-004, the 2nd Phase IIa of ABX464, its lead drug candidate in the treatment of HIV, today before market opening.